Relmada Therapeutics
RLMDRelmada Therapeutics is a publicly traded biotech firm focused on developing differentiated therapies that combine durable efficacy, favorable safety, and ease of administration. With a seasoned leadership team and a strong financial foundation bolstered by recent financing, the company is executing on a strategic pipeline anchored by NDV-01 for bladder cancer and sepranolone for compulsive disorders. Relmada's approach prioritizes clinical validation, clear development pathways, and addressing well-defined patient populations to create long-term value.
RLMD · Stock Price
Historical price data
AI Company Overview
Relmada Therapeutics is a publicly traded biotech firm focused on developing differentiated therapies that combine durable efficacy, favorable safety, and ease of administration. With a seasoned leadership team and a strong financial foundation bolstered by recent financing, the company is executing on a strategic pipeline anchored by NDV-01 for bladder cancer and sepranolone for compulsive disorders. Relmada's approach prioritizes clinical validation, clear development pathways, and addressing well-defined patient populations to create long-term value.
Technology Platform
Focus on innovative drug delivery and neurosteroid mechanisms; lead asset NDV-01 utilizes a sustained-release intravesical formulation designed for prolonged local drug exposure and minimal systemic toxicity.
Pipeline
11| Drug | Indication | Stage | Watch |
|---|---|---|---|
| REL-1017 + Placebo | Major Depressive Disorder | Phase 3 | |
| REL-1017 + Placebo | Major Depressive Disorder | Phase 3 | |
| NDV-01 (sustained-release gemcitabine-docetaxel) | Bladder (Urothelial, Transitional Cell) Cancer | Phase 3 | |
| NDV-01 (sustained-release gemcitabine-docetaxel) | Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) | Phase 3 | |
| NDV-01 (sustained-release gemcitabine-docetaxel) | Bladder (Urothelial, Transitional Cell) Cancer | Phase 3 |
Opportunities
Risk Factors
Competitive Landscape
In NMIBC, NDV-01 competes with BCG, chemotherapy, and newer gene/immunotherapies, differentiating via its sustained-release combo and in-office convenience. In Prader-Willi, sepranolone faces limited direct competition, targeting an unmet need with a novel neurosteroid mechanism.
